Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium

Research output: Contribution to journalJournal articleResearchpeer-review

  1. PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Nonsulfated cholecystokinins in cerebral neurons

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. PKA, novel PKC isoforms, and ERK is mediating PACAP auto-regulation via PAC1R in human neuroblastoma NB-1 cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Oral rimegepant for migraine prevention

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP)-containing nerves surround cerebral blood vessels. The peptides have potent vasodilator properties via smooth muscle cell receptors and activation of adenylate cyclase. The purpose of this study was to describe the effects of two putative VIP/PACAP receptor antagonists and the distribution of the receptor protein in rat brain vessels.

METHODS: The vascular effects of VIP, PACAP-27 and PACAP-38 were investigated in segments of rat middle cerebral artery (MCA) by pressurized arteriography, and in a wire myograph. The antagonistic responses to PACAP6-38 and PG99-465 were evaluated. In addition, the receptor subtypes for VIP and PACAP (VPAC1, VPAC2 and PAC1) were visualized in the rat middle cerebral artery by immunohistochemistry and Western blotting.

RESULTS: In the perfusion model, abluminal but not luminal VIP, PACAP-27 and PACAP-38 caused concentration-dependent relaxations of the MCA (27.1±0.2%, 25.2±0.4% and 0.3±0.1%, respectively). In the wire myograph, there was no significant difference in potency of the peptides in the MCA. In both systems, PACAP6-38 and PG99-465 inhibited the VIP induced relaxation. Western blot showed the presence of the receptor proteins in cerebral vasculature and immunohistochemistry showed that all three receptors are present and located in the cytoplasm of smooth muscle cells.

CONCLUSION: In both systems, the two blockers antagonized the relaxant VIP effect; the potency order of agonists and the immunohistochemistry suggest the presence of the dilatory VPAC1 and VPAC2 receptors on the smooth muscle cells.

Original languageEnglish
JournalNeuropeptides (Edinburgh)
Volume47
Issue number2
Pages (from-to)85-92
Number of pages8
ISSN0143-4179
DOIs
Publication statusPublished - Apr 2013
Externally publishedYes

    Research areas

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid, Angiography, Animals, Blotting, Western, Calcium, Cerebral Arteries, Electromyography, Fluorescent Antibody Technique, Immunohistochemistry, Isometric Contraction, Male, Muscle, Smooth, Vascular, RNA, Messenger, Rats, Rats, Sprague-Dawley, Rats, Wistar, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I, Receptors, Vasoactive Intestinal Peptide, Receptors, Vasoactive Intestinal Peptide, Type II, Vasoconstrictor Agents

ID: 44872213